Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: Arm C of the AcSé-ESMART trial
PURPOSE: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with molecularly enriched recurrent/refractory malignancies. - PATIENTS AND METHODS: Adavosertib was administered orally, twice...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2024
|
| In: |
Clinical cancer research
Year: 2024, Jahrgang: 30, Heft: 4, Pages: 741-753 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-23-2959 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-23-2959
|
| Verfasserangaben: | Susanne A. Gatz, Anne C. Harttrampf, Caroline Brard, Francisco Bautista, Nicolas André, Samuel Abbou, Jonathan Rubino, Windy Rondof, Marc Deloger, Marc Rübsam, Lynley V. Marshall, Daniel Hübschmann, Souad Nebchi, Isabelle Aerts, Estelle Thebaud, Emilie De Carli, Anne Sophie Defachelles, Xavier Paoletti, Robert Godin, Kowser Miah, Peter G.S. Mortimer, Gilles Vassal, and Birgit Geoerger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1906924104 | ||
| 003 | DE-627 | ||
| 005 | 20251030091146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241025s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-23-2959 |2 doi | |
| 035 | |a (DE-627)1906924104 | ||
| 035 | |a (DE-599)KXP1906924104 | ||
| 035 | |a (OCoLC)1475316821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gatz, Susanne Andrea |d 1972- |e VerfasserIn |0 (DE-588)123280842 |0 (DE-627)706240138 |0 (DE-576)29363551X |4 aut | |
| 245 | 1 | 0 | |a Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies |b Arm C of the AcSé-ESMART trial |c Susanne A. Gatz, Anne C. Harttrampf, Caroline Brard, Francisco Bautista, Nicolas André, Samuel Abbou, Jonathan Rubino, Windy Rondof, Marc Deloger, Marc Rübsam, Lynley V. Marshall, Daniel Hübschmann, Souad Nebchi, Isabelle Aerts, Estelle Thebaud, Emilie De Carli, Anne Sophie Defachelles, Xavier Paoletti, Robert Godin, Kowser Miah, Peter G.S. Mortimer, Gilles Vassal, and Birgit Geoerger |
| 264 | 1 | |c 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: December 5, 2023 | ||
| 500 | |a Gesehen am 25.10.2024 | ||
| 520 | |a PURPOSE: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with molecularly enriched recurrent/refractory malignancies. - PATIENTS AND METHODS: Adavosertib was administered orally, twice every day on Days 1 to 3 and carboplatin intravenously on Day 1 of a 21-day cycle, starting at 100 mg/m2/dose and AUC 5, respectively. Patients were enriched for molecular alterations in cell cycle and/or homologous recombination (HR). - RESULTS: Twenty patients (median age: 14.0 years; range: 3.4-23.5) were included; 18 received 69 treatment cycles. Dose-limiting toxicities were prolonged grade 4 neutropenia and grade 3/4 thrombocytopenia requiring transfusions, leading to two de-escalations to adavosertib 75 mg/m2/dose and carboplatin AUC 4; no recommended phase II dose was defined. Main treatment-related toxicities were hematologic and gastrointestinal. Adavosertib exposure in children was equivalent to that in adults; both doses achieved the cell kill target. Overall response rate was 11% (95% confidence interval, 0.0-25.6) with partial responses in 2 patients with neuroblastoma. One patient with medulloblastoma experienced unconfirmed partial response and 5 patients had stable disease beyond four cycles. Seven of these eight patients with clinical benefit had alterations in HR, replication stress, and/or RAS pathway genes with or without TP53 alterations, whereas TP53 pathway alterations alone (8/10) or no relevant alterations (2/10) were present in the 10 patients without benefit. - CONCLUSIONS: Adavosertib-carboplatin combination exhibited significant hematologic toxicity. Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA-damaging therapy in molecularly enriched pediatric cancers. | ||
| 650 | 4 | |a Adolescent | |
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols | |
| 650 | 4 | |a Arm | |
| 650 | 4 | |a Carboplatin | |
| 650 | 4 | |a Carcinoma | |
| 650 | 4 | |a Cell Cycle Proteins | |
| 650 | 4 | |a Child | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Protein-Tyrosine Kinases | |
| 650 | 4 | |a Pyrazoles | |
| 650 | 4 | |a Pyrimidinones | |
| 650 | 4 | |a Young Adult | |
| 700 | 1 | |a Harttrampf, Anne C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brard, Caroline |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bautista, Francisco |e VerfasserIn |4 aut | |
| 700 | 1 | |a André, Nicolas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abbou, Samuel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rubino, Jonathan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rondof, Windy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deloger, Marc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rübsam, Marc |e VerfasserIn |0 (DE-588)1380110084 |0 (DE-627)1939611962 |4 aut | |
| 700 | 1 | |a Marshall, Lynley V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hübschmann, Daniel |d 1981- |e VerfasserIn |0 (DE-588)1099133653 |0 (DE-627)858143798 |0 (DE-576)469237082 |4 aut | |
| 700 | 1 | |a Nebchi, Souad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aerts, Isabelle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thebaud, Estelle |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Carli, Emilie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Defachelles, Anne Sophie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paoletti, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Godin, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Miah, Kowser |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mortimer, Peter G. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vassal, Gilles |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geoerger, Birgit |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 30(2024), 4 vom: Feb., Seite 741-753 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies Arm C of the AcSé-ESMART trial |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:4 |g month:02 |g pages:741-753 |g extent:13 |a Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies Arm C of the AcSé-ESMART trial |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-23-2959 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241025 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1099133653 |a Hübschmann, Daniel |m 1099133653:Hübschmann, Daniel |d 50000 |e 50000PH1099133653 |k 0/50000/ |p 12 | ||
| 998 | |g 1380110084 |a Rübsam, Marc |m 1380110084:Rübsam, Marc |d 160000 |e 160000PR1380110084 |k 0/160000/ |p 10 | ||
| 999 | |a KXP-PPN1906924104 |e 4602583393 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Susanne A. Gatz, Anne C. Harttrampf, Caroline Brard, Francisco Bautista, Nicolas André, Samuel Abbou, Jonathan Rubino, Windy Rondof, Marc Deloger, Marc Rübsam, Lynley V. Marshall, Daniel Hübschmann, Souad Nebchi, Isabelle Aerts, Estelle Thebaud, Emilie De Carli, Anne Sophie Defachelles, Xavier Paoletti, Robert Godin, Kowser Miah, Peter G.S. Mortimer, Gilles Vassal, and Birgit Geoerger"]},"person":[{"given":"Susanne Andrea","display":"Gatz, Susanne Andrea","role":"aut","family":"Gatz"},{"role":"aut","family":"Harttrampf","given":"Anne C.","display":"Harttrampf, Anne C."},{"role":"aut","family":"Brard","display":"Brard, Caroline","given":"Caroline"},{"role":"aut","family":"Bautista","given":"Francisco","display":"Bautista, Francisco"},{"role":"aut","family":"André","given":"Nicolas","display":"André, Nicolas"},{"given":"Samuel","display":"Abbou, Samuel","family":"Abbou","role":"aut"},{"given":"Jonathan","display":"Rubino, Jonathan","role":"aut","family":"Rubino"},{"display":"Rondof, Windy","given":"Windy","family":"Rondof","role":"aut"},{"role":"aut","family":"Deloger","display":"Deloger, Marc","given":"Marc"},{"given":"Marc","display":"Rübsam, Marc","role":"aut","family":"Rübsam"},{"role":"aut","family":"Marshall","given":"Lynley V.","display":"Marshall, Lynley V."},{"family":"Hübschmann","role":"aut","given":"Daniel","display":"Hübschmann, Daniel"},{"family":"Nebchi","role":"aut","display":"Nebchi, Souad","given":"Souad"},{"display":"Aerts, Isabelle","given":"Isabelle","family":"Aerts","role":"aut"},{"family":"Thebaud","role":"aut","display":"Thebaud, Estelle","given":"Estelle"},{"family":"De Carli","role":"aut","given":"Emilie","display":"De Carli, Emilie"},{"family":"Defachelles","role":"aut","given":"Anne Sophie","display":"Defachelles, Anne Sophie"},{"display":"Paoletti, Xavier","given":"Xavier","family":"Paoletti","role":"aut"},{"family":"Godin","role":"aut","display":"Godin, Robert","given":"Robert"},{"role":"aut","family":"Miah","display":"Miah, Kowser","given":"Kowser"},{"display":"Mortimer, Peter G. S.","given":"Peter G. S.","family":"Mortimer","role":"aut"},{"family":"Vassal","role":"aut","display":"Vassal, Gilles","given":"Gilles"},{"family":"Geoerger","role":"aut","display":"Geoerger, Birgit","given":"Birgit"}],"recId":"1906924104","note":["Online verfügbar: December 5, 2023","Gesehen am 25.10.2024"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies","subtitle":"Arm C of the AcSé-ESMART trial","title_sort":"Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies"}],"id":{"eki":["1906924104"],"doi":["10.1158/1078-0432.CCR-23-2959"]},"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"relHost":[{"name":{"displayForm":["American Association for Cancer Research"]},"recId":"325489971","title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1557-3265"],"eki":["325489971"],"zdb":["2036787-9"]},"origin":[{"publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","dateIssuedDisp":"1995-","publisher":"AACR"}],"language":["eng"],"part":{"issue":"4","pages":"741-753","extent":"13","text":"30(2024), 4 vom: Feb., Seite 741-753","volume":"30","year":"2024"},"pubHistory":["1.1995 -"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"disp":"Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies Arm C of the AcSé-ESMART trialClinical cancer research","type":{"bibl":"periodical","media":"Online-Ressource"}}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"2024"}]} | ||
| SRT | |a GATZSUSANNPHASEIIIST2024 | ||